PA
RIGL icon

Parallel Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Parallel Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.19K Buy
340
+263
+342% +$8.84K ﹤0.01% 2790
2025
Q4 		$3.3K Buy
+77
New +$2.9K ﹤0.01% 2986
2022
Q2 		– Sell
-31
Closed -$1K – 3293
2022
Q1 		$1K Buy
31
+20
+182% +$541 ﹤0.01% 2820
2021
Q4 		$0 Buy
+11
New +$332 ﹤0.01% 3258

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's RIGL Position: Q1 2026 in Review

Parallel Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 342% in Q1 2026, buying an estimated $8.84K and bringing the position to 340 shares worth $9.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2790.

Parallel Advisors first reported a position in RIGL in Q4 2021 and has held it in 4 quarters since. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Parallel Advisors held 340 shares of Rigel Pharmaceuticals worth $9.19K as of Q1 2026.
  • Parallel Advisors bought 263 Rigel Pharmaceuticals shares in Q1 2026, an estimated $8.84K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2790 holding.
  • Parallel Advisors first reported a position in Rigel Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.